Synthesis and PKC binding of a new class of a-ring diversifiable bryostatin analogues utilizing a double asymmetric hydrogenation and cross-coupling strategy.
暂无分享,去创建一个
[1] S. Buchwald,et al. Catalysts for Suzuki-Miyaura coupling processes: scope and studies of the effect of ligand structure. , 2005, Journal of the American Chemical Society.
[2] Ryoji Noyori,et al. Asymmetric hydrogenation of .beta.-keto carboxylic esters. A practical, purely chemical access to .beta.-hydroxy esters in high enantiomeric purity , 1987 .
[3] T. Hashimoto,et al. Bis(((S)-binaphthoxy)(isopropoxy)titanium) oxide as a mu-oxo-type chiral Lewis acid: application to catalytic asymmetric allylation of aldehydes. , 2003, Journal of the American Chemical Society.
[4] P. Blumberg,et al. Highly lipophilic phorbol esters as inhibitors of specific [3H]phorbol 12,13-dibutyrate binding. , 1985, Cancer research.
[5] G. Schwartz,et al. Bryostatin-1: A Novel PKC Inhibitor in Clinical Development , 2003, Cancer investigation.
[6] B. Bienfait,et al. The Lipophilicity of Phorbol Esters as a Critical Factor in Determining the Pattern of Translocation of Protein Kinase C δ Fused to Green Fluorescent Protein* , 2000, The Journal of Biological Chemistry.
[7] M. Wills,et al. Chemistry and clinical biology of the bryostatins. , 2000, Bioorganic & medicinal chemistry.
[8] John P. Wolfe,et al. A Highly Active Catalyst for Palladium-Catalyzed Cross-Coupling Reactions: Room-Temperature Suzuki Couplings and Amination of Unactivated Aryl Chlorides , 1998 .
[9] R. Mohammad,et al. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[10] T. Meyer,et al. Function oriented synthesis: the design, synthesis, PKC binding and translocation activity of a new bryostatin analog. , 2004, Current drug discovery technologies.
[11] D. Alkon,et al. Dual effects of bryostatin-1 on spatial memory and depression. , 2005, European journal of pharmacology.
[12] C. Holmquist,et al. The conversion of olefins to β-keto esters: Ozonolysis of olefins followed by in situ reduction with tin(II) chloride in the presence of ethyl diazoacetate. , 1990 .
[13] N. Lindquist,et al. Potent cytotoxins produced by a microbial symbiont protect host larvae from predation , 2004, Oecologia.
[14] D. Alkon,et al. Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[15] Mark Frigerio,et al. The chemistry and biology of the bryostatin antitumour macrolides. , 2002, Natural product reports.
[16] S. Hannick,et al. An improved procedure for the Blaise reaction: a short, practical route to the key intermediates of the saxitoxin synthesis , 1983 .
[17] Paul A Wender,et al. Role of the A-ring of bryostatin analogues in PKC binding: synthesis and initial biological evaluation of new A-ring-modified bryologs. , 2005, Organic letters.
[18] Gang Zhao,et al. One-pot preparation of β-hydroxy esters catalysed by a bis(cyclopentadienyl)titanium(IV) dichloride–zinc system , 1992 .
[19] Christopher S. Poss,et al. Two-directional chain synthesis : an application to the synthesis of (+)-mycoticin A , 1993 .
[20] Blaise Lippa,et al. The practical synthesis of a novel and highly potent analogue of bryostatin. , 2002 .
[21] Shadan Ali,et al. Sensitization of human breast cancer cells to gemcitabine by the protein kinase C modulator bryostatin 1 , 2003, Cancer Chemotherapy and Pharmacology.
[22] T. Katsuki,et al. A rapid esterification by means of mixed anhydride and its application to large-ring lactonization. , 1979 .